What the July 2026 FDA Cancer Approvals Mean

Four cancer approvals in six days

Between July 9 and July 14, 2026, the FDA posted four cancer approval notices. They cover multiple myeloma, bladder cancer, breast cancer, and a group of tumors defined by one gene change.

Read together, they show how narrow modern approvals have become. Each one names a cancer type and a stage. Most also name a prior treatment or a lab result. The exact wording is the point. Here is what each notice says.

Multiple myeloma: a shot instead of a drip

On July 9 the FDA cleared a new form of isatuximab-irfc. It is sold as Sarclisa Escena. The drug now comes as a shot under the skin. Doctors call that route subcutaneous. The older form goes into a vein through a drip.

Myeloma is a cancer of plasma cells in the bone marrow. The approval covers three drug combinations already used for it. The dose is 1,400 mg.

The main trial was called IRAKLIA. It split 531 people between the shot and the drip. Each group also took pomalidomide and dexamethasone. The shot led to a response in 71.1% of people. The drip led to a response in 70.5%. A response means the tumor burden shrank by a set amount.

This is a change in how a drug is given. It is not a new drug. It matters for time spent in the chair.

Bladder cancer: the plan shifts around surgery

On July 10 the FDA approved a new use for two drugs given together. They are pembrolizumab and enfortumab vedotin. The pair is given before surgery and again after it.

The cancer is muscle invasive bladder cancer. The surgery is a cystectomy, which removes the bladder.

An earlier approval covered only people who could not take cisplatin chemotherapy. This one covers everyone who is fit for the operation.

The trial was KEYNOTE-B15/EV-304. It enrolled 808 people. Half got the new pair. Half got chemotherapy before surgery. The main measure was event-free survival. That is time until the cancer came back or spread, or the person died. The hazard ratio was 0.53. A hazard ratio under 1 favors the new arm. Overall survival was better too, at 0.65.

Breast cancer: an option after hormone therapy stops working

On July 14 the FDA approved gedatolisib. It is sold as Revtorpyk. It is taken with fulvestrant, with or without palbociclib.

The label is narrow. The cancer must be hormone receptor-positive and HER2-negative. It must be locally advanced or have spread. The tumor must not carry a PIK3CA mutation. And the person must have had at least one round of endocrine therapy for advanced disease.

The trial was VIKTORIA-1. It split 392 people three ways. The measure was progression-free survival. That is how long people went before the cancer grew again.

The three-drug arm reached a median of 9.3 months. The two-drug arm reached 7.4 months. Fulvestrant alone reached 2.0 months. Survival data were not yet mature. Labeled warnings include mouth sores, skin reactions, and high blood sugar.

Solid tumors: a gene fusion, not an organ

Selpercatinib was also cleared on July 14. It is sold as Retevmo. The FDA moved it from accelerated approval to full approval.

The use is unusual. It covers any solid tumor that carries a RET gene fusion. A gene fusion happens when two genes get joined by mistake. The joined pair makes a protein that drives growth.

So what qualifies a person is the fusion, not the organ. An FDA-approved test has to find it. Adults and children aged 2 and over are covered.

The evidence came from a trial called LIBRETTO-001. It looked at 75 people whose fusion-positive tumors were not lung or thyroid cancer. Just under half, 47%, responded. Responses lasted a median of 24.5 months. This is targeted therapy in its purest form. It only reaches you if the testing was done first.

What this does not mean

• An approval is a permission. It is not a recommendation, and it does not mean the drug fits your cancer.
• Three of the four depend on a lab result or a past treatment. Without that match, the label does not apply.
• Newer is not always better for one person. Two of these trials had immature survival data.
• None of this is a reason to pause or change treatment on your own.
• Coverage rules and infusion center schedules can still differ from what the label allows.

When to raise this with your team

Bring it up if one of these fits you. You have myeloma and travel a long way for infusions. You have muscle invasive bladder cancer and surgery is being planned. You have hormone receptor-positive, HER2-negative breast cancer that grew during endocrine therapy. Or you have an advanced solid tumor that has never had broad gene testing.

That last case is the most common gap. Ask whether your tumor was tested for gene fusions. Ask whether the result is in your chart. Our guide to biomarker testing shows what the report looks like.

Approval news moves fast. Standard care moves more slowly, and for good reason. Our page on trials versus standard treatment explains the gap between the two.

Sources

• FDA: Oncology (Cancer)/Hematologic Malignancies Approval Notifications
• FDA approves gedatolisib with fulvestrant, with or without palbociclib
• FDA grants traditional approval to selpercatinib for RET fusion-positive solid tumors
• FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer
• FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

How this page was made

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.